Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Efient

Bristol-Myers Squibb (BMS) building

Speedy NICE appraisal backs BMS’ Opdivo/Yervoy combination

But HTA body doesn't find Roche's Cotellic/Zelboraf cost-effective

- PMLiVE

Vertex’ cystic fibrosis drug too costly, says NICE

£104,000 per patient price tag is "too high" for the drug’s “modest” short term benefit

Biosimilars – the Brexit of the pharmaceutical industry?

In this article, Senior Consultant Jenna Earl explains what factors influence the uptake of biosimilars in the UK, comparing them to the same principles that help us navigate the complexities...

Blue Latitude Health

- PMLiVE

NICE gives Bayer’s Elyea a provisional ‘no’ for first-line use

Company says recommendation goes against Royal College guidance for BRVO

National Institute for Health and Care Excellence NICE logo

NICE gives green light to Sanofi’s Jevtana for prostate cancer

Undisclosed discount for NHS encourages U-turn to back the chemotherapy drug

National Institute for Health and Care Excellence NICE logo

NICE backs freer use of SGLT2 inhibitors for diabetes

Recommendation positions Invokana, Forxiga and Jardiance as first-line treatments

Roche's Perjeta pertuzumab

NICE rejects Roche’s breast cancer drug Perjeta

Says the treatment's long-term benefits are unclear

National Institute for Health and Care Excellence NICE logo

Cancer charities criticise NICE’s ‘last-century methodology’

Group of 15 claims many new prostate cancer drugs will now ‘struggle to gain approval’

National Institute for Health and Care Excellence NICE logo

NICE rejects Opdivo for lung cancer once again

Says PD-1 inhibitor is too expensive to be used routinely

National Institute for Health and Care Excellence NICE logo

NICE persuaded to back Praluent as well as Repatha

Comes after Sanofi follows Amgen in discounting the price of its drug

National Institute for Health and Care Excellence NICE logo

NICE changes tack on Sanofi’s prostate cancer drug Jevtana

Approves the therapy for NHS use after accepting undisclosed additional discount 

National Institute for Health and Care Excellence NICE logo

NICE backs first Duchenne muscular dystrophy drug

Reverses original decision to reject the therapy in favour of more data

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links